Lupin appoints Paul McGarty as Prez, Lupin Pharmaceuticals

Mumbai, Aug 3 Pharma major, Lupin Ltd today announced the appointment of Paul McGarty as the President of its US subsidiary, Lupin Pharmaceuticals. McGarty has over 25-years experience in the pharmaceutical industry spanning across brand and specialty pharmaceutical companies, a press release issued here stated. Most recently, as the CEO of Nycomed US, McGarty successfully transformed the company from a topical manufacturer into a dermatology specialty company with a brand and generic business. Under his leadership, Nycomed US emerged as a leading fully-integrated dermatology specialty company in the US, the release said. He has also served as a member of the Executive Committee and Board of Directors for the Generic Pharmaceutical Association (GPhA), as well as a member of the National Association of Chain Drug Stores (NACDS) Foundation Board, the release said. "With more than 25 years of experience in pharmaceutical operations as well as commercial functions, in both generic and branded business, Paul brings invaluable experience and leadership skills to Lupin's growth plans in the US," Lupin Pharmaceuticals, Chief Executive Officer, Vinita Gupta, said.

Generic Pharmaceutical Association Accepts Synomics Pharma for Membership

WAREHAM-Synomics Pharmaceutical Services, LLC, a leader in pre-clinical and clinical bioanalytical services, storage stability, and analytical testing services for the pharmaceutical industry, announced that the Generic Pharmaceutical Association (GPhA®) has named Synomics Pharma as a contract research organization member. GPhA represents the manufacturers and distributors of finished generic pharmaceuticals and bulk active pharmaceutical chemicals, and suppliers of other goods and services to the generic drug industry.

Synomics Pharma, a Smithers Group company, provides a broad portfolio of pre-clinical and clinical services in support of drug development through production. Michael Hochschwender, President and CEO of The Smithers Group, said, "Synomics Pharma's membership in the GPhA allows us to be at the forefront of issues facing the manufacturers and distributors of generic drugs. Our clients in the generics industry benefit as we actively develop our service offerings based on their needs and continually adapt our quality system to meet changing regulatory requirements. We are providing unique services which are specific to the needs of manufacturers and distributors in the generic industry."

"Synomics Pharma has a quality management system that is recognized as a benchmark throughout the generic and pharmaceutical industry," added John Pirro, Vice President and Chief Operating Officer of Synomics Pharma. "We see this membership as mutually beneficial for Synomics Pharma and for all GPhA members, as our mission is to provide quality service to the generics industry that exceeds expectations."